xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06021613</url>
    </required_header>
    <id_info>
      <org_study_id>23-39656</org_study_id>
      <nct_id>NCT06021613</nct_id>
    </id_info>
    <brief_title>The MARY-JANE Cannabis and Heart Rhythm Trial</brief_title>
    <official_title>Marijuana and Acute Risk of Arrhythmia- Joint Abstinence and Exposure</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of California, San Francisco</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>University of California, San Francisco</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Despite recreational cannabis now being legal in 23 states, where more than 100 million&#xD;
        Americans reside, studies on the actual health effects are limited. This study is a&#xD;
        randomized trial, where each participant will be instructed to consume or avoid cannabis on&#xD;
        randomly assigned days during a 14-day monitoring period. The goal of this study is to answer&#xD;
        the question:&#xD;
  &#xD;
        &quot;Does cannabis use increase the frequency of 'early' and abnormal heart beats?&quot;&#xD;
  &#xD;
        During the 14-day period, participants will wear an external heart monitor, a glucose&#xD;
        monitor, and a fitness tracker to track heart rhythm, glucose levels, step counts, and sleep&#xD;
        health. Participants will use a mobile app or a text messaging service for daily&#xD;
        instructions/reminders on cannabis use, and short surveys. The investigators ask that&#xD;
        participants smoke or vape cannabis at least once on days they are instructed to consume&#xD;
        cannabis. Compelling evidence of heart and other health effects would be important to the&#xD;
        clinical care of our patients.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This study is designed as a case-crossover randomized trial, where each participant will be&#xD;
        instructed to consume or avoid inhaled cannabis on randomly assigned days during a 14-day&#xD;
        monitoring period. Participants will be asked to smoke or vape cannabis at least once on days&#xD;
        they are instructed to consume cannabis. Participants will also wear an external&#xD;
        electrocardiographic (ECG) monitor, a continuous glucose monitor, and a fitness tracker for&#xD;
        up to two weeks while utilizing a mobile application or text messaging service to receive&#xD;
        daily instructions/reminders on cannabis use, and short surveys. The investigators will&#xD;
        compare participant self-report of cannabis consumption, glucose monitoring, fitness levels,&#xD;
        sleep health, and heart rhythm data in order to better understand the relationship between&#xD;
        acute cannabis consumption and heart rhythm changes. A total of 100 participants will be&#xD;
        enrolled at the UCSF study site.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">November 2023</start_date>
    <completion_date type="Anticipated">November 2030</completion_date>
    <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Other</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in PAC and PVC frequencies</measure>
      <time_frame>Baseline and after completion of cannabis consumption, up to 2 weeks</time_frame>
      <description>Participants will be wearing a continuously recording ECG monitor for two weeks. The primary outcome will be change in premature atrial contraction (PAC) and PVC frequency due to cannabis consumption or avoidance during the monitoring period.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Change in SVT episodes</measure>
      <time_frame>Baseline and after completion of cannabis consumption, up to 2 weeks</time_frame>
      <description>Participants will be wearing a continuously recording ECG monitor for two weeks. A secondary outcome will be change in supraventricular tachycardia (SVT) episodes due to cannabis consumption or avoidance during the monitoring period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in VT episodes</measure>
      <time_frame>Baseline and after completion of cannabis consumption, up to 2 weeks</time_frame>
      <description>Participants will be wearing a continuously recording ECG monitor for two weeks. A secondary outcome will be change in ventricular tachycardia (VT) episodes due to cannabis consumption or avoidance during the monitoring period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Mean daily glucose levels</measure>
      <time_frame>2 weeks</time_frame>
      <description>Participants will be wearing a continuous glucose monitor that will record serum glucose levels. A secondary outcome will be difference in mean daily glucose levels due to cannabis consumption or avoidance during the monitoring period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Mean step count</measure>
      <time_frame>2 weeks</time_frame>
      <description>Participants will be wearing a fitness tracker that will record step counts. A secondary outcome will be difference in mean step counts due to cannabis consumption or avoidance during the monitoring period.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Mean sleep duration</measure>
      <time_frame>2 weeks</time_frame>
      <description>Participants will be wearing a fitness tracker that will record sleep duration. A secondary outcome will be difference in mean sleep duration due to cannabis consumption or avoidance during the monitoring period.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">100</enrollment>
    <condition>Premature Atrial Contractions</condition>
    <condition>Premature Ventricular Contractions</condition>
    <arm_group>
      <arm_group_label>Case-crossover</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will be randomized in two-day blocks to consume then avoid cannabis (&quot;Start: On Cannabis&quot;) or avoid then consume cannabis (&quot;Start: Off Cannabis&quot;). Using an case-crossover strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, or the Mosio text messaging software for clinical research, participants will receive instructions and answer questions to help researchers and physicians understand the relationship between inhaled cannabis and heart rhythm.</description>
    </arm_group>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>Randomized instructions</intervention_name>
      <description>Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.&#xD;
  Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.</description>
      <arm_group_label>Case-crossover</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Are age 21 or older&#xD;
  &#xD;
            2. Have a smartphone&#xD;
  &#xD;
            3. Are able to use the Eureka mobile application and Mosio text messaging software&#xD;
  &#xD;
            4. Have inhaled cannabis in the past month and on at least four different days in the&#xD;
               same week in the past year&#xD;
  &#xD;
            5. Are willing to consume and abstain from inhaled cannabis for no more than two&#xD;
               consecutive days as instructed over the 14-day trial period&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Currently pregnant or trying to get pregnant&#xD;
  &#xD;
            2. Have a medical reason to avoid cannabis&#xD;
  &#xD;
            3. Are unwilling to avoid all forms of cannabis consumption on days instructed to abstain&#xD;
               from cannabis&#xD;
  &#xD;
            4. Are currently taking anti-arrhythmic medications&#xD;
  &#xD;
            5. Have a history of atrial fibrillation or heart failure&#xD;
  &#xD;
            6. Have congenital heart disease&#xD;
  &#xD;
            7. Have an implantable cardioverter-defibrillator or pacemaker&#xD;
  &#xD;
            8. Have had a previous cardiac ablation procedure&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>21 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Gregory M Marcus, MD, MAS</last_name>
      <role>Principal Investigator</role>
      <affiliation>University of California, San Francisco</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Gregory M Marcus, MD, MAS</last_name>
      <phone>415-476-5706</phone>
      <email>greg.marcus@ucsf.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>UCSF Medical Center at Parnassus</name>
        <address>
          <city>San Francisco</city>
          <state>California</state>
          <zip>94143</zip>
          <country>United States</country>
        </address>
      </facility>
    </location>
    <location>
      <facility>
        <name>UCSF Medical Center at Mission Bay</name>
        <address>
          <city>San Francisco</city>
          <state>California</state>
          <zip>94158</zip>
          <country>United States</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4.</citation>
      <PMID>23831166</PMID>
    </reference>
    <reference>
      <citation>Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.</citation>
      <PMID>33501848</PMID>
    </reference>
    <reference>
      <citation>Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, Horst C, Kaldjian A, Matyasz T, Scott KW, Bui AL, Campbell M, Duber HC, Dunn AC, Flaxman AD, Fitzmaurice C, Naghavi M, Sadat N, Shieh P, Squires E, Yeung K, Murray CJL. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020 Mar 3;323(9):863-884. doi: 10.1001/jama.2020.0734.</citation>
      <PMID>32125402</PMID>
    </reference>
    <reference>
      <citation>Marcus GM, Vittinghoff E, Whitman IR, Joyce S, Yang V, Nah G, Gerstenfeld EP, Moss JD, Lee RJ, Lee BK, Tseng ZH, Vedantham V, Olgin JE, Scheinman MM, Hsia H, Gladstone R, Fan S, Lee E, Fang C, Ogomori K, Fatch R, Hahn JA. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Ann Intern Med. 2021 Nov;174(11):1503-1509. doi: 10.7326/M21-0228. Epub 2021 Aug 31.</citation>
      <PMID>34461028</PMID>
    </reference>
    <reference>
      <citation>Lin AL, Nah G, Tang JJ, Vittinghoff E, Dewland TA, Marcus GM. Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur Heart J. 2022 Dec 14;43(47):4933-4942. doi: 10.1093/eurheartj/ehac558.</citation>
      <PMID>36257330</PMID>
    </reference>
    <reference>
      <citation>Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, Psaty BM, Sotoodehnia N, Gottdiener JS, Marcus GM. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013 Dec 3;159(11):721-8. doi: 10.7326/0003-4819-159-11-201312030-00004.</citation>
      <PMID>24297188</PMID>
    </reference>
    <reference>
      <citation>Marcus GM, Dewland TA. Premature Atrial Contractions: A Wolf in Sheep's Clothing? J Am Coll Cardiol. 2015 Jul 21;66(3):242-244. doi: 10.1016/j.jacc.2015.04.069. No abstract available.</citation>
      <PMID>26184617</PMID>
    </reference>
    <reference>
      <citation>Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, Psaty BM, Sotoodehnia N, Gottdiener JS, Marcus GM. Ventricular Ectopy as a Predictor of Heart Failure and Death. J Am Coll Cardiol. 2015 Jul 14;66(2):101-9. doi: 10.1016/j.jacc.2015.04.062.</citation>
      <PMID>26160626</PMID>
    </reference>
    <reference>
      <citation>Marcus GM. Evaluation and Management of Premature Ventricular Complexes. Circulation. 2020 Apr 28;141(17):1404-1418. doi: 10.1161/CIRCULATIONAHA.119.042434. Epub 2020 Apr 27.</citation>
      <PMID>32339046</PMID>
    </reference>
    <reference>
      <citation>Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, Joyce S, Yilmaz D, Yang V, Kessedjian T, Wilson E, Yang M, Chang K, Wall G, Olgin JE. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. N Engl J Med. 2023 Mar 23;388(12):1092-1100. doi: 10.1056/NEJMoa2204737.</citation>
      <PMID>36947466</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 28, 2023</study_first_submitted>
    <study_first_submitted_qc>August 28, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 1, 2023</study_first_posted>
    <last_update_submitted>August 31, 2023</last_update_submitted>
    <last_update_submitted_qc>August 31, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Cannabis</keyword>
    <keyword>Marijuana</keyword>
    <keyword>Weed</keyword>
    <keyword>Arrhythmias</keyword>
    <keyword>Cardiac Ectopy</keyword>
    <keyword>PACs</keyword>
    <keyword>PVCs</keyword>
    <keyword>Heart Rhythm</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Premature Birth</mesh_term>
      <mesh_term>Ventricular Premature Complexes</mesh_term>
      <mesh_term>Atrial Premature Complexes</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06021613
  org study id: 23-39656
  nct id: NCT06021613
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Despite recreational cannabis now being legal in 23 states, where more than 100 million
        Americans reside, studies on the actual health effects are limited. This study is a
        randomized trial, where each participant will be instructed to consume or avoid cannabis on
        randomly assigned days during a 14-day monitoring period. The goal of this study is to answer
        the question:
  
        "Does cannabis use increase the frequency of 'early' and abnormal heart beats?"
  
        During the 14-day period, participants will wear an external heart monitor, a glucose
        monitor, and a fitness tracker to track heart rhythm, glucose levels, step counts, and sleep
        health. Participants will use a mobile app or a text messaging service for daily
        instructions/reminders on cannabis use, and short surveys. The investigators ask that
        participants smoke or vape cannabis at least once on days they are instructed to consume
        cannabis. Compelling evidence of heart and other health effects would be important to the
        clinical care of our patients.
  This study is designed as a case-crossover randomized trial, where each participant will be
        instructed to consume or avoid inhaled cannabis on randomly assigned days during a 14-day
        monitoring period. Participants will be asked to smoke or vape cannabis at least once on days
        they are instructed to consume cannabis. Participants will also wear an external
        electrocardiographic (ECG) monitor, a continuous glucose monitor, and a fitness tracker for
        up to two weeks while utilizing a mobile application or text messaging service to receive
        daily instructions/reminders on cannabis use, and short surveys. The investigators will
        compare participant self-report of cannabis consumption, glucose monitoring, fitness levels,
        sleep health, and heart rhythm data in order to better understand the relationship between
        acute cannabis consumption and heart rhythm changes. A total of 100 participants will be
        enrolled at the UCSF study site.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Other
  masking: None (Open Label)
  measure: Change in PAC and PVC frequencies
  time frame: Baseline and after completion of cannabis consumption, up to 2 weeks
  description: Participants will be wearing a continuously recording ECG monitor for two weeks. The primary outcome will be change in premature atrial contraction (PAC) and PVC frequency due to cannabis consumption or avoidance during the monitoring period.
  measure: Change in SVT episodes
  time frame: Baseline and after completion of cannabis consumption, up to 2 weeks
  description: Participants will be wearing a continuously recording ECG monitor for two weeks. A secondary outcome will be change in supraventricular tachycardia (SVT) episodes due to cannabis consumption or avoidance during the monitoring period.
  measure: Change in VT episodes
  time frame: Baseline and after completion of cannabis consumption, up to 2 weeks
  description: Participants will be wearing a continuously recording ECG monitor for two weeks. A secondary outcome will be change in ventricular tachycardia (VT) episodes due to cannabis consumption or avoidance during the monitoring period.
  measure: Mean daily glucose levels
  time frame: 2 weeks
  description: Participants will be wearing a continuous glucose monitor that will record serum glucose levels. A secondary outcome will be difference in mean daily glucose levels due to cannabis consumption or avoidance during the monitoring period.
  measure: Mean step count
  time frame: 2 weeks
  description: Participants will be wearing a fitness tracker that will record step counts. A secondary outcome will be difference in mean step counts due to cannabis consumption or avoidance during the monitoring period.
  measure: Mean sleep duration
  time frame: 2 weeks
  description: Participants will be wearing a fitness tracker that will record sleep duration. A secondary outcome will be difference in mean sleep duration due to cannabis consumption or avoidance during the monitoring period.
  arm group label: Case-crossover
  arm group type: Experimental
  description: Participants will be randomized in two-day blocks to consume then avoid cannabis ("Start: On Cannabis") or avoid then consume cannabis ("Start: Off Cannabis"). Using an case-crossover strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, or the Mosio text messaging software for clinical research, participants will receive instructions and answer questions to help researchers and physicians understand the relationship between inhaled cannabis and heart rhythm.
  intervention type: Behavioral
  intervention name: Randomized instructions
  description: Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.
  Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.
  arm group label: Case-crossover
  criteria: 
  gender: All
  minimum age: 21 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: Gregory M Marcus, MD, MAS
  role: Principal Investigator
  affiliation: University of California, San Francisco
  last name: Gregory M Marcus, MD, MAS
  phone: 415-476-5706
  email: greg.marcus@ucsf.edu
  facility: 
  facility: 
  country: United States
  citation: Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4.
  PMID: 23831166
  citation: Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.
  PMID: 33501848
  citation: Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, Horst C, Kaldjian A, Matyasz T, Scott KW, Bui AL, Campbell M, Duber HC, Dunn AC, Flaxman AD, Fitzmaurice C, Naghavi M, Sadat N, Shieh P, Squires E, Yeung K, Murray CJL. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020 Mar 3;323(9):863-884. doi: 10.1001/jama.2020.0734.
  PMID: 32125402
  citation: Marcus GM, Vittinghoff E, Whitman IR, Joyce S, Yang V, Nah G, Gerstenfeld EP, Moss JD, Lee RJ, Lee BK, Tseng ZH, Vedantham V, Olgin JE, Scheinman MM, Hsia H, Gladstone R, Fan S, Lee E, Fang C, Ogomori K, Fatch R, Hahn JA. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Ann Intern Med. 2021 Nov;174(11):1503-1509. doi: 10.7326/M21-0228. Epub 2021 Aug 31.
  PMID: 34461028
  citation: Lin AL, Nah G, Tang JJ, Vittinghoff E, Dewland TA, Marcus GM. Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur Heart J. 2022 Dec 14;43(47):4933-4942. doi: 10.1093/eurheartj/ehac558.
  PMID: 36257330
  citation: Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, Psaty BM, Sotoodehnia N, Gottdiener JS, Marcus GM. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013 Dec 3;159(11):721-8. doi: 10.7326/0003-4819-159-11-201312030-00004.
  PMID: 24297188
  citation: Marcus GM, Dewland TA. Premature Atrial Contractions: A Wolf in Sheep's Clothing? J Am Coll Cardiol. 2015 Jul 21;66(3):242-244. doi: 10.1016/j.jacc.2015.04.069. No abstract available.
  PMID: 26184617
  citation: Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, Psaty BM, Sotoodehnia N, Gottdiener JS, Marcus GM. Ventricular Ectopy as a Predictor of Heart Failure and Death. J Am Coll Cardiol. 2015 Jul 14;66(2):101-9. doi: 10.1016/j.jacc.2015.04.062.
  PMID: 26160626
  citation: Marcus GM. Evaluation and Management of Premature Ventricular Complexes. Circulation. 2020 Apr 28;141(17):1404-1418. doi: 10.1161/CIRCULATIONAHA.119.042434. Epub 2020 Apr 27.
  PMID: 32339046
  citation: Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, Joyce S, Yilmaz D, Yang V, Kessedjian T, Wilson E, Yang M, Chang K, Wall G, Olgin JE. Acute Effects of Coffee Consumption on Health among Ambulatory Adults. N Engl J Med. 2023 Mar 23;388(12):1092-1100. doi: 10.1056/NEJMoa2204737.
  PMID: 36947466
  responsible party type: Sponsor
  mesh term: Premature Birth
  mesh term: Ventricular Premature Complexes
  mesh term: Atrial Premature Complexes
  sharing ipd: No